DE69229729D1 - Wundheilung - Google Patents

Wundheilung

Info

Publication number
DE69229729D1
DE69229729D1 DE69229729T DE69229729T DE69229729D1 DE 69229729 D1 DE69229729 D1 DE 69229729D1 DE 69229729 T DE69229729 T DE 69229729T DE 69229729 T DE69229729 T DE 69229729T DE 69229729 D1 DE69229729 D1 DE 69229729D1
Authority
DE
Germany
Prior art keywords
composition
disclosed
wound healing
wounds
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69229729T
Other languages
English (en)
Other versions
DE69229729T3 (de
DE69229729T2 (de
Inventor
Mark Ferguson
David M Foreman
Mamta Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Victoria University of Manchester
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10692386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69229729(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Victoria University of Manchester, University of Manchester filed Critical Victoria University of Manchester
Publication of DE69229729D1 publication Critical patent/DE69229729D1/de
Application granted granted Critical
Publication of DE69229729T2 publication Critical patent/DE69229729T2/de
Publication of DE69229729T3 publication Critical patent/DE69229729T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
DE69229729T 1991-03-28 1992-03-30 Wundheilung Expired - Lifetime DE69229729T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9106678 1991-03-28
GB919106678A GB9106678D0 (en) 1991-03-28 1991-03-28 Wound healing
PCT/GB1992/000570 WO1992017206A1 (en) 1991-03-28 1992-03-30 Wound healing

Publications (3)

Publication Number Publication Date
DE69229729D1 true DE69229729D1 (de) 1999-09-09
DE69229729T2 DE69229729T2 (de) 2000-01-13
DE69229729T3 DE69229729T3 (de) 2007-10-18

Family

ID=10692386

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229729T Expired - Lifetime DE69229729T3 (de) 1991-03-28 1992-03-30 Wundheilung

Country Status (13)

Country Link
US (4) US5662904A (de)
EP (1) EP0585242B2 (de)
JP (3) JP3333507B2 (de)
AT (1) ATE182792T1 (de)
AU (1) AU661840B2 (de)
CA (2) CA2387247C (de)
DE (1) DE69229729T3 (de)
DK (1) DK0585242T4 (de)
ES (1) ES2136618T5 (de)
GB (1) GB9106678D0 (de)
GR (1) GR3030924T3 (de)
IE (1) IE921013A1 (de)
WO (1) WO1992017206A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US7189410B1 (en) * 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
WO1993009800A1 (en) * 1991-11-14 1993-05-27 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
AU3609893A (en) * 1992-01-29 1993-09-01 La Jolla Cancer Research Foundation Methods of controlling the proliferation of macrophages
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
WO1994002595A1 (en) * 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
AU669256B2 (en) * 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
WO1994029452A2 (en) * 1993-06-09 1994-12-22 Ribozyme Pharmaceuticals, Inc. Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US20030130324A1 (en) * 1993-11-19 2003-07-10 Johnston W. Mcavoy Method for preventing or controlling cataract
WO1995016032A1 (en) * 1993-12-09 1995-06-15 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
JPH09510101A (ja) * 1994-03-07 1997-10-14 イミュソル,インコーポレイティド 再狭窄のためのリボザイム療法
GB9405046D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
AU710153B2 (en) * 1994-03-29 1999-09-16 Renovo Limited Wound healing
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9702943D0 (en) 1997-02-13 1997-04-02 Univ Manchester Wound healing
EP1009421B1 (de) * 1997-08-27 2004-06-30 President And Fellows Of Harvard College Zusammenstellungen zur verbesserten wundheilung
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
WO2000051566A1 (en) * 1999-03-04 2000-09-08 United States Surgical Corporation Scar reduction
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
US7078390B1 (en) 1999-10-15 2006-07-18 Gentier Biosystems Incorporation Ribozymes to growth factor originating in human platelet
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
AU9407501A (en) * 2000-06-23 2002-04-22 Medigenes Agent for reduction of scar formation by using wound alkalinization
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US20040235791A1 (en) * 2002-01-25 2004-11-25 Gruskin Elliott A. Scar reduction
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
US7759472B2 (en) 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
CA2536188A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック, インコーポレイテッド ヒト化抗TGF−β抗体
DE102004025881A1 (de) * 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
US20070275874A1 (en) * 2004-09-03 2007-11-29 Yale University Use of Leptin in Wound Healing
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
CA2665717C (en) * 2005-10-25 2016-01-19 Women's & Children's Health Research Institute Methods and compositions comprising a flightless i antagonist for modulating wound repair
US8353881B2 (en) 2005-12-28 2013-01-15 Abbott Diabetes Care Inc. Infusion sets for the delivery of a therapeutic substance to a patient
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US9119582B2 (en) 2006-06-30 2015-09-01 Abbott Diabetes Care, Inc. Integrated analyte sensor and infusion device and methods therefor
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
US8206296B2 (en) 2006-08-07 2012-06-26 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US8641618B2 (en) 2007-06-27 2014-02-04 Abbott Diabetes Care Inc. Method and structure for securing a monitoring device element
US8085151B2 (en) 2007-06-28 2011-12-27 Abbott Diabetes Care Inc. Signal converting cradle for medical condition monitoring and management system
CA2741028A1 (en) * 2008-10-21 2010-04-29 Novodermix International Limited Composition for treatment of epithelial tissue
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
EP4218792A1 (de) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Zusammensetzung zur behandlung von myeloproliferativen erkrankungen
JP7267664B2 (ja) 2017-05-04 2023-05-02 アクセルロン ファーマ インコーポレイテッド Tgfベータ受容体ii型融合タンパク質およびその使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
DE3382562D1 (de) * 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
CA1230591A (en) * 1983-06-03 1987-12-22 Charles A. Frolik PURIFIED TRANSFORMING GROWTH FACTOR-.beta. DERIVED FROM HUMAN PLATELETS AND PLACENTAS
DE3629640A1 (de) * 1986-08-30 1988-03-03 Behringwerke Ag Verwendung monoklonaler antikoerper zur therapie von tumoren
US4708948A (en) * 1984-04-20 1987-11-24 The United States Of America As Represented By The Department Of Health And Human Services Substantially purified tumor growth inhibitory factor
DE3588058T3 (de) * 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Knorpel-induzierende Polypeptid-Faktoren aus Knochen
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5168051A (en) * 1985-03-22 1992-12-01 Genentech, Inc. Nucleic acid encoding TGF-β its uses
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE60059B1 (en) * 1985-04-19 1994-05-18 Oncogene Science Inc Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
JPH01502669A (ja) * 1987-03-13 1989-09-14 アムジエン・インコーポレーテツド 精製された血小板由来の成長因子及びその精製方法
EP0418234B1 (de) * 1988-06-08 1994-03-23 Genentech, Inc. Nukleinsäure, die tgf-b3 kodiert, und ihre verwendung
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
US5118791A (en) * 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
WO1991004748A1 (en) * 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
JPH05509320A (ja) * 1990-06-25 1993-12-22 オーエスアイ ファーマシューティカルズ,インコーポレイティド 組織誘導型腫瘍成長抑制物質、その調製及び使用方法
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
GB9101645D0 (en) * 1991-01-25 1991-03-06 British Bio Technology Compounds
AU1426792A (en) * 1991-02-04 1992-09-07 Oncogene Science, Inc. Inhibition of multidrug transport by transforming growth factor beta and uses thereof
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU710153B2 (en) * 1994-03-29 1999-09-16 Renovo Limited Wound healing

Also Published As

Publication number Publication date
DK0585242T4 (da) 2007-07-02
CA2387247C (en) 2009-05-19
CA2105652A1 (en) 1992-09-29
US5662904A (en) 1997-09-02
AU661840B2 (en) 1995-08-10
EP0585242A1 (de) 1994-03-09
DE69229729T3 (de) 2007-10-18
GB9106678D0 (en) 1991-05-15
DK0585242T3 (da) 1999-12-06
US20050287139A1 (en) 2005-12-29
DE69229729T2 (de) 2000-01-13
US20100152095A1 (en) 2010-06-17
US20020187149A1 (en) 2002-12-12
EP0585242B2 (de) 2007-03-07
JPH06506205A (ja) 1994-07-14
GR3030924T3 (en) 1999-11-30
WO1992017206A1 (en) 1992-10-15
ES2136618T3 (es) 1999-12-01
JP2002275094A (ja) 2002-09-25
CA2387247A1 (en) 1992-10-15
CA2105652C (en) 2005-09-06
JP2006001949A (ja) 2006-01-05
JP3333507B2 (ja) 2002-10-15
EP0585242B1 (de) 1999-08-04
ATE182792T1 (de) 1999-08-15
AU1436892A (en) 1992-11-02
IE921013A1 (en) 1992-10-07
ES2136618T5 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
DE69229729D1 (de) Wundheilung
PT1009425E (pt) Cicatrizacao de feridas
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
HK1046096A1 (en) Solutions and methods for inhibitions of pain, inflammation and cartilage degradation
BR0014996A (pt) Método para prevenir ou melhorar a dor de um ferimento fechado cirurgicamente em um indivìduo, e, emplastro
NO985575L (no) FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
SE9101840L (sv) Ny medicinsk anvaendning
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
CO5280202A1 (es) Metodos de tratamiento y metodos de rastreo de farmacos
DE69937070D1 (de) Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
MY118982A (en) Method of reducing tissue damage associated with ischemia
ES2131331T3 (es) Uso de benzotiofenos para la preparacion de un medicamento para reducir la formacion de cicatrices en la curacion de heridas.
Todd Side-hole suction for ear surgery

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: RENOVO LTD., MANCHESTER, GB

8328 Change in the person/name/address of the agent

Free format text: SERWE, K., DIPL.-ING., PAT.-ANW., 54290 TRIER

8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: MOSELPATENT TRIERPATENT, 54290 TRIER

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE SERWE & DR. WAGNER, 54290 TRIER